~~<i id='5150A1AFC5'><strike id='5150A1AFC5'><tt id='5150A1AFC5'><pre id='5150A1AFC5'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：explore 2025-10-02 08:54:33 Page View：1619

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Ending racial health disparities hinges on penalties, political will
Next article： Wildfire smoke exposes gaps in outdoor worker protections

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

1:29FILE-ThiscombooffileimagesshowsFacebookCEOMarkZuckerberg,left,andTeslaandSpaceXCEOElonMusk.ElonM

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Moderna hits safety problems in bold bid to reinvent medicine

AramBoghosianforSTATSANFRANCISCO—ModernaTherapeutics,themosthighlyvaluedprivatecompanyinbiotech,hasr